BRIDGEWATER, N.J., Oct. 17,
2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq:
INSM), a people-first global biopharmaceutical company striving to
deliver first- and best-in-class therapies to transform the lives
of patients facing serious diseases, today announced that it will
release its third-quarter 2024 financial results on Thursday,
October 31, 2024.
Insmed management will host a conference call for investors
beginning at 8:00 a.m. ET on Thursday,
October 31, 2024, to discuss the financial results and
provide a business update.
Shareholders and other interested parties may participate in the
conference call by dialing (888) 210-2654 (U.S.) and (646) 960-0278
(international) and referencing access code 7862189. The call will
also be webcast live on the Company's website at
www.insmed.com.
A replay of the conference call will be accessible approximately
1 hour after its completion through November
7, 2024, by dialing (800) 770-2030 (U.S.) and (609)
800-9909 (international) and referencing access code 7862189. A
webcast of the call will also be archived for 90 days under the
Investor Relations section of the Company's website at
www.insmed.com.
About Insmed
Insmed Incorporated is a people-first global biopharmaceutical
company striving to deliver first- and best-in-class therapies to
transform the lives of patients facing serious diseases. The
Company is advancing a diverse portfolio of approved and mid- to
late-stage investigational medicines as well as cutting-edge drug
discovery focused on serving patient communities where the need is
greatest. Insmed's most advanced programs are in pulmonary and
inflammatory conditions, including a therapy approved in the
United States, Europe, and Japan to treat a chronic,
debilitating lung disease. The Company's early-stage research
programs encompass a wide range of technologies and modalities,
including gene therapy, AI-driven protein engineering, protein
manufacturing, RNA end-joining, and synthetic rescue.
Headquartered in Bridgewater, New Jersey, Insmed has
offices and research locations throughout the United
States, Europe, and Japan. Insmed is proud to be
recognized as one of the best employers in the biopharmaceutical
industry, including spending three consecutive years as the No.
1 Science Top Employer.
Visit www.insmed.com to learn more.
Contact:
Investors:
Bryan Dunn
Executive Director, Investor Relations
Insmed
(646) 812-4030
bryan.dunn@insmed.com
Media:
Mandy Fahey
Vice President, Corporate Communications
Insmed
(732) 718-3621
amanda.fahey@insmed.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/insmed-to-host-third-quarter-2024-financial-results-conference-call-on-thursday-october-31-2024-302271683.html
SOURCE Insmed Incorporated